Lonza's 2026 Estrategia: Nt'a̲ni pa ya compradores CDMO ar péptidos

¿Temu̲ bí mä realmente ar CEO Lonza dige ar carrera mfeni CDMO?

Peptides Factory Wholesale Teduglutide Lonza’s Capital Markets Day comments emphasized adding capacity to support its expected growth and pursuing value from capabilities. This is management’s stated strategy, not evidence that peptide manufacturing capacity is universally adequate.

Read the two halves together and the position is coherent rather than contradictory. The company will still add capacity; it just will not add it to win a volume contest. What it wants to be paid for is the capability wrapped around the molecule, which is the same shift the expanded DNA-to-IND offering points to: a longer handover per program rather than more litres per year.

One scope flag before you apply any of this to peptides. In the same session the CEO described “continued undersupply, high and too high utilization of the globally available capacity” for mammalian capacity. That is a cell-culture observation, not a statement about peptide API. The strategic posture transfers to peptide buying; the utilization remark does not.

Is the peptide CDMO industry really done adding capacity?

Capacity remains relevant, alongside technical fit and quality. One company’s strategic statement does not establish that capacity has ceased to differentiate suppliers across the sector.

The two best public indicators point in different directions because they measure different things. One provider’s 2025 industry survey reports that average annual growth in operating capacity slipped by 1.0% for mammalian and 0.9% for microbial production, as new suites came online faster than pipelines could fill them, while CDMO service sales grew 17.1% a year. The peptide CDMO market forecast puts the peptide CDMO market at USD 2.1 billón en 2025, USD 2.3 billón en 2026 and USD 5.0 'nar billón ya 2033, an 11.7% compound annual growth rate.

The apparent contradiction dissolves once you name the units. One provider’s survey measures the direction of capacity utilization in cell-culture platforms. Grand View models revenue in a different modality. Neither is a peptide capacity utilization figure, and we would not print one as if it were. What both support is a single buyer-facing conclusion: the supply base is expanding, so a supplier’s willingness to build square metres tells you almost nothing about whether it can make your molecule.

n No public figure in these sources gives peptide-specific capacity or utilization. Treat any supplier presentation that quotes one without a methodology as marketing.

The criterion to carry forward: ask what the added capacity is configured to do, not how much of it there is.

Why is production volume the wrong yardstick for complex peptide programs?

Because the failure modes that hurt you are chemical, and volume does not address them. A supplier can have all the reactor litres in the world and still return a batch where your peptide is not the majority species.

The base rates are sobering. An analysis of roughly 1,800 synthesised sequences found that 3.6% of syntheses showed no or minor signal for the desired peptide, a complete failure, and that in 14% of cases the ordered peptide was not the majority of the peptide mass. Only 87% met a threshold of more than 50% abundance. That is research-grade, high-throughput material, not API, but it establishes the shape of the risk: difficult sequences fail at a rate you cannot average away with more capacity.

Conventional SPPS is not generally limited to 15–20 residues. Secuencia, route, scale and purification determine feasibility; both longer successes and difficult short sequences are possible.

Pro Tip The EU guideline’s impurity thresholds and the 50%-abundance criterion measure different things. A batch can fail the abundance test while every individual impurity sits below the 1.0% m. Do not let a supplier answer one with the other.

For an aggregation-prone 40-mer with two disulfide bonds, Ya nt'a̲ni da determinan ar programa ya dige ar estrategia acoplamiento, disciplina ar limitación, control oxidación ne resolución analítica. ninguno dige'u̲ neki ja 'nar hoja mfeni.

What does fit-for-purpose CDMO capability include, step by step?

mfeni ajuste pa ár propósito ge 'nar cadena coordinada, hingi 'nar menú ja ar xe̲ni. ar ntsa̲ ar nu'bu̲ 'nar proveedor to guiar bí ar selección ruta a través de ntsa̲ liberación komongu 'nar sola secuencia controlada, ko ya nt'ot'e analíticos diseñados pa ya impurezas da realmente produce ar química.

'bu̲i ko nä'ä ar especificación da contener. ya pruebas especificación da espera ar guía ar UE mfa̲ts'i 'bu̲i ar identificación, pureza Nxoge ne 'natho, especies ar be̲xu molecular mar hñets'i ya SEC — LC ko ya especies nombradas (dímeros, �, oligomers, agregados, ke 'nar línea genérica 'nar HMW impurezas 'nar hingi ar aceptable), ensayo, Identidad ne contenido contra-iones, residual TFA, dehe, residual solvents, elemental impurities, Endotoxinas bacterianas ne pureza microbiológica.

gem'bu̲ pregunte Temu̲ ar proceso controla nä'ä detectarán esas pruebas. The impurity origins the guideline names include deletion and truncated sequences from incomplete coupling and capping, insertion sequences, epimerisation, cleavage-related substances, and degradation routes such as oxidation, �, aspartimide formation, diketopiperazine and pyroglutamic acid formation.

Finally, ask how the methods were validated. ICH Q2(R2), adopted in November 2023, ties validation characteristics to analytical purpose: Especificidad, working range, accuracy and precision, with robustness established during development.

Nuwa ge nä'ä mä 'nar cadena coordinada jar práctica. ma equipo funciona jar fase sólida, fase líquida, síntesis combinada líquido-sólido ne inversa fase sólida junto con fermentación microbiana, ar miligramo ar gramo ar escala, ko pureza crudo ma 99%, TFA komongu ar contador ar ion ne acetato predeterminado, cloruro wa mpa̲ti amonio da 'mui. ntsa̲ liberación cubre MS pa identidad ne HPLC pa pureza, ko endotoxina, contenido ar contador iones, biocarga, sterility, humedad ne confirmación secuencia disponible nä'ä mahyoni, y producción corre ar síntesis a través de HPLC preparativa ne liofilización ja 'nar nsa̲di 100 'nar sala 'Beni.

How do you compare peptide suppliers on evidence rather than claims?

ya comparas jar documentos da cruzan 'na ma'na. afirmación 'nar proveedor ge 'nar hmä; evidencia 'nar proveedor ge 'nar 'bede ya lote da conduce 'nar cromatograma, which leads to a validated method, which leads to a stability protocol. When we assess a peptide CDMO selection file, that chain is what we test first, because lot-to-lot consistency cannot be verified from a stack of unattached PDFs.

The regulatory baseline has moved, and that changes what you should request. The EU synthetic-peptide guideline in force since June 2026 sets peptide-related impurity thresholds at 0.1% reporting, 0.5% identification and 1.0% calificación, because synthetic peptides sit outside ICH Q3A. Methods must be sensitive enough to meet that 0.1% umbral ar informe, and where impurities co-elute the 1.0% qualification threshold applies unless justified.

For process changes, know which framework you are borrowing. The comparability expectations in ICH Q5E require analytical evidence that a change has no adverse impact on quality, safety or efficacy, but the guideline does not prescribe a fixed analytical program. It is scoped to biological products, so use its logic, not its letter, for a synthetic peptide.

Key Takeaway A usable data package cross-references lot to chromatogram to method to stability protocol. If any link is missing, you cannot verify lot-to-lot consistency, and the claim is unverified.

Where does scale-up from mg to kg actually break down?

Scale-up can change mixing, mass transfer, impurity profiles and purification needs. An analytical method is qualified for its purpose and sample matrix, not simply a milligram or kilogram batch label; assess whether changed material remains within demonstrated coverage.

The mass data make the mechanism visible. Peptide manufacturing’s material intensity reports process mass intensity for commercial and Phase 3 solid-phase processes ranging from 1,684 to 34,585 kg of waste per kg of product, averaging about 13,063 for peptides of 6 to 43 residues, with downstream processing accounting for roughly 50% of that intensity because of dilute product solutions and long chromatographic gradients. The same analysis puts liquid-phase processes at an average of about 3,984, kontra ar aproximadamente 8,300 for biopharmaceuticals and 168 to 308 for small molecules.

The practical reading is not that solid-phase is bad. It is that route choice is a scale-up decision, and a supplier who cannot discuss liquid-phase or hybrid options for a long or difficult sequence has a narrower toolkit than your program may need. The same analysis notes that mass intensity per amino acid stays essentially static across development phases for solid-phase processes, which means the inefficiency does not fix itself as you advance.

n No peer-reviewed figure quantifies mg-to-kg yield loss for a specific peptide. Judge scale-up readiness from the mechanism and from the supplier’s own lot history, not from a quoted percentage.

What belongs on a peptide CDMO shortlist scorecard?

Weight capability above capacity, and make capacity a single line rather than the headline. That is the practical translation of a value-capture posture into a buying decision.

Compare each supplier’s relevant capability, quality system, capacity and continuity evidence. Large providers and specialists vary; neither type has a guaranteed advantage in difficult-sequence work or redundancy.

puntuación kadu̲ 'nar 'ñu dige evidencias gí xka hyandi realmente, hingi dige nä'ä 'nar nte empresarial llamado prometido. nu'bu̲ 'nar proveedor hingi tsa̲ da suministrar ar evidencia pa 'nar 'ñu mar hñets'i be̲xu, nä'ä ge 'nar puntuación inferior, hingi 'nar neutral.

nu'bu̲ gi ñoho 'nar hñäki dige ho ár secuencia sienta kontra nuya criterios, ma equipo to hnu paquete técnico kontra ar calificación ne bí mä Temu̲ ar evidencia 'be̲di 'be̲tho comprometer.

nt'a̲ni frecuentes

�?

�; A. r, not peptide API, so treat the “value capture” framing as a signal about how large CDMOs are positioning themselves, h.

Can a specialist supplier carry a program from mg to kg?

Often yes, m. �, �: ask for lot history across the scale range, m. f.

My program is mid-transfer with a thin data package. What should I request first?

e, n, content, nzäm'bu, process and quality records as needed. Yoho xingu ya documentos hingi xi verificar nga̲tho ya aspecto 'nar proveedor wa ya lote.

Did the July 2026 FDA withdrawal change what I should ask for?

aumenta ar mahyoni da conciencia reguladora komongu 'nar criterio selección. Gi 'ya̲ni Temu̲ versión orientación 'nar proveedor xí utilizando ne honja xi influido jar ár 'be̲fi impureza ne caracterización, 'Me̲fa verifique ya requisitos pertinentes ko ár propio equipo regulador nu'bu confiar jar kwalkiera nu'ä ja 'nar archivo.

Njäts'i nu'bu

Ar encuadre ar carrera mfeni nzäm'bu̲ ge 'nar proxy. Nä'ä 'nar programa péptido realmente t'ot'e ge 'nar proveedor nä'ä to da 'nar secuencia desafiante, Demostrar nä'ä produció, Ne lleva tanto ar proceso ne ar paquete analítico a través de escalar — mañä hinda perder ar evidencia. CEO 'nar proveedor bí mä ke ar empresa xi ja 'nar carrera captura hmädi, Ne pa ya compradores, nä'ä mahyoni komongu 'nar recordatorio útil: stop scoring suppliers on tonnage and start scoring them on the documents they can put in front of you.

The takeaway is a working method, hingi 'nar veredicto. Weight difficult-sequence track record, analytical depth and route flexibility above capacity. Demand that every lot number lead to a chromatogram, a validated method and a stability protocol. Treat a missing link as a red flag rather than a gap to be filled later. And check that the regulatory baseline your supplier cites is the one currently in force, not the one that was withdrawn.

Score your current shortlist against the table above, line by line, on evidence you have seen. Where a high-weight line has no evidence behind it, request it before the next round of discussions, and let the answers decide the ranking. If you would like our team to review your sequence and the package you have collected so far, get in touch with your requirements and we will tell you what is missing.

Xiaoxia Chen

New Drug R&D Technician d: Target discovery, structure-activity relationship (SAR) analysis, peptide-drug conjugates (PDCs), and the development of anti-aging and metabolic peptides.

About the Author Latest Posts

Profile: Xiaoxia Chen has led the early discovery and preclinical research for several metabolic and tumor-targeted peptide drugs. She is not only proficient in high-throughput screening of peptide libraries but also skilled in utilizing AI-assisted computational biology for de novo peptide sequence design. Currently, she is leading a team dedicated to the in-depth research and development of next-generation multifunctional agonists (such as dual- or triple-target fat-reducing peptides) and highly active tissue-repair peptides.

• Amyloid Beta 1–42 Aggregation — Investigate Preparation Comparability 2026年11月12日
• Peptide Purification Services — Write a Brief for Purity and Usable Recovery 2026年11月12日
• Peptide Shipping Excursions — Record the Exposure Before Deciding Suitability 2026年11月12日
• Reconstituted Peptide Sampling — Repeated Stock Access Versus Separate Portions 2026年11月11日
• Péptidos disolución — distinguir claridad, Recuperación ne dätä hnini monomérico 2026年11月11日

Verificación ar hechos & Directrices editoriales

HMUNTS'UJE proceso verificación hechos

Priorizamos ar exactitud ne ya 'mui ja ma contenido. Nuwa ar Honja mantenemos altos estándares:

1. revisión expertos: Ga̲tho ya xeni Nthuts'i ya revisados ya expertos materia.
2. i: ungumfädi xí respaldada ya creíble, c.
3. o: m.

p: r

o

m.

• e: t.
• i: i, trends, g.
• Commitment to Quality: Reviewers ensure clarity, correctness, and completeness.

Look for the expert-reviewed label to read content you can trust.